top of page

★★

血糖降下薬4剤の心血管抑制効果を比較

Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-656. doi: 10.1016/S2213-8587(23)00171-7. Epub 2023 Jul 24. PMID: 37499675.

23/7/24

Lancet DE

観察研究

米国退役軍人データベース観察28万人。
脳卒中,心筋梗塞,全死亡の複合は、SU薬と比べてハザード SGLT2i 0.77 [0.74-0.80], GLP-1 0.78[0.74-0.81],DPP4i 0.90[0.86-0.93]

bottom of page